BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Eisai-Biogen Alzheimer’s Drug Shows Amyloid Reduction, Disease-Modifying Effect

  Eisai and Biogen announced positive updates on the Phase IIB 201 and open-label extension studies they are conducting on the use of lecanemab to treat early Alzheimer’s Disease.

  November 11, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Genetown

  Acrivon Nets $100 Million and Licenses Cast-Off Lilly Oncology Drug

  Five months after the company launched, Acrivon Therapeutics secured $100 million in Series B financing to support the clinical development of a cancer asset it licensed from Eli Lilly.

  November 11, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  BioSpace Movers & Shakers, Nov. 12

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

  November 11, 2021

   · 

  5 min read

   · 

  Alex Keown
• 

  Drug Development

  Research Roundup: How Age Impacts Post-COVID Antibody Numbers and More

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

  November 11, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  New AI Collaborations Reflect Rapid Growth in Pharmaceutical Industry

  As the capabilities have been proven, AI is establishing a firm foothold in the key areas of R&D, drug development, clinical trials, and, to some extent, patient-facing products.

  November 11, 2021

   · 

  5 min read

   · 

  Gail Dutton
• 

  BioForest

  Gates Foundation Pours $90 Million into Promising New Pneumococcal Vaccine

  The Bill & Melinda Gates Foundation is taking up the cause for pneumococcal infection with a $90 million investment in Seattle area’s Inventprise.

  November 11, 2021

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Business

  Women’s Health Gets a Boost as Merck Spinoff Acquires New Pipeline

  Organon is paying $75 million upfront, taking on about $9 million of Forendo debt, and up to $270 million in various development and regulatory milestones.

  November 11, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Scientists Explore SARS-CoV-2 Mega Vaccine

  Scientists are conducting research into the possibility of creating a vaccine that activates T cells that targets not just SARS-CoV-2 but also its variations, even the ones that cause common colds.

  November 11, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Career Advice

  How Should Your Resume Reflect a Years-Long Gap Between Jobs?

  How can you show employers that your skills are current, despite being out of work for months or years?

  November 11, 2021

   · 

  2 min read

   · 

  Kymberlie Krieger
• 

  Deals

  Biotech Companies Launch or Plan IPOs: Vaxxinity, Genenta and Enetrada

  Vaxxinity set its initial public offering price at $13 per share, raising $76 million. The company was launched in April via consolidation of the vaccine development efforts of COVAXX and United Neuroscience.

  November 11, 2021

   · 

  3 min read

   · 

  Mark Terry